Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of Differential Tumor Subtypes of T1 Bladder Cancer

ABSTRACT: Identification of Differential Tumor Subtypes of T1 Bladder Cancer

PROVIDER: PRJNA645686 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12202400.fastq.gz	Fastqsanger.gz
	SRR12202401.fastq.gz	Fastqsanger.gz
	SRR12202402.fastq.gz	Fastqsanger.gz
	SRR12202403.fastq.gz	Fastqsanger.gz
	SRR12202404.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 125

Similar Datasets

Identification of Differential Tumor Subtypes of T1 Bladder Cancer

Project description:Stage T1 bladder cancers have the highest progression and recurrence rates of all non-muscle invasive bladder tumors. T1 tumors are heterogeneous; while most T1 patients are treated with BCG, many will progress and die from bladder cancer, and particularly aggressive tumors could be treated by early cystectomy. To better understand the molecular heterogeneity of T1 cancers, we performed transcriptome profiling and unsupervised clustering, identifying five consensus subtypes of T1 tumors treated with reTUR, induction and maintenance BCG. The T1-LumGU subtype was associated with CIS (6/13, 46% of all CIS), had high E2F1 and EZH2 expression, and enriched E2F target and G2M checkpoint Hallmarks. T1-Inflam was inflamed and infiltrated with immune cells. While most T1 tumors were classified as luminal papillary, the T1-TLum subtype had the highest median Luminal Papillary score and FGFR3 expression, no recurrence events, and the fewest copy number gains. T1-Myc and T1-Early subtypes had the most recurrences (14/30 within 24 months), highest median MYC expression, and, when combined, had significantly worse recurrence-free survival than the other three subtypes. T1-Early had 5 (38%) recurrences within the first 6 months of BCG, and repressed IFN-alpha and IFN-gamma Hallmarks and inflammation. We developed a single-patient T1 classifier and validated our subtype biology in a second cohort of T1 tumors. Future research will be necessary to validate the proposed T1 subtypes and to determine if therapies can be individualized for each subtype.

2020-07-13 | GSE154261 | GEO

Expression analysis of human stage Ta and stage T1 bladder tumours

Project description:Expression data derived from this analysis was used for transcriptional subtyping and to compare expression features of genomic subgroups In this dataset, we include the expression data obtained from 113 stage Ta and 104 stage T1 bladder tumours

2021-02-22 | GSE163209 | GEO

Identification of Lineage-specific Transcriptional Factor–defined Molecular Subtypes in Small Cell Bladder Cancer

Project description:Three subtypes of small cell/neuroendocrine bladder cancers (SCBCs) were identified: ASCL1, NEUROD1, and POU2F3. These subtypes are with neuroendocrine (NE) level, immune signature, and antibody-drug conjugate (ADC) target implications.

2024-06-13 | GSE269750 | GEO

Tumor T1 Sectors

Project description:The following CGH experiments were conducted on four sectors (S1-S4) from a single primary ductal carcinoma tumor (T1).

2009-07-10 | GSE16598 | GEO

Whole-exome sequencing of paired tumour/blood of 58 T1 stage bladder cancer patients

Project description:To understand the molecular determinants that underpin the clinical heterogeneity of non-muscle-invasive bladder cancer (NMIBC) we carried out whole-exome sequencing (WES) of stage T1 bladder tumours to identify prognostic biomarkers and novel therapeutic targets. The study includes paired tumour/blood samples of 58 T1 stage bladder cancer patients.

| EGAS00001005765 | EGA

Dual role of GRHL3 in bladder carcinogenesis is associated with histological subtypes

Project description:Grainyhead-like transcription factor 3 (GRHL3) is known to affect cancer development depending on subtypes in various entities. Here, we analyzed the subtype-specific role of GRHL3 in bladder carcinogenesis comparing common urothelial carcinoma (UC) with squamous bladder cancers (sq-BLCA). We examined GRHL3 mRNA and protein expression in cohorts of patient samples, its prognostic role as well as its functional impact on tumorigeneses in different molecular and histopathological subtypes of bladder cancer. We showed for GRHL3 a reverse expression in squamous and urothelial bladder cancer subtypes. Stably GRHL3 overexpressing EJ28 and SCaBER in vitro models revealed a tumor suppressive function in squamous and a oncogenic role in the urothelial cancer cells affecting cell migratory and invasive capacities. Transcriptomic profiling demonstrated highly subtype specific GRHL3 regulated expression networks coined by enrichment of genes involved in integrin mediated pathways. In SCaBER loss of RhoA GTPase activity was demonstrated associated with co-regulation of EIF4E3, a potential tumor suppressor gene. Thus, our data provide for the first time a detailed insight into the role of the transcription factor GRHL3 in different histopathological subtypes of bladder cancer.

2024-06-20 | GSE241298 | GEO

Biochemical network analysis of protein-protein interactions to monitor the course of T1 bladder cancer patients

Project description:Mass spectrometry-based personalized medicine was used to uncover key information in T1-stage bladder cancer (BC) patients and used as a tool to aid clinical decision making. The urinary proteome of patients with recurring versus non-recurring T1-stage BC were compared to uncover information for clinical decision making. Our results suggest the urinary myeloperoxidase to cubilin ratio as a new tool to address recurrence as well as dysregulation of the inflammatory and immune systems as drivers of a worsening disease course. Furthermore, dysregulation of neutrophil extracellular traps (NETs) is pinpointed as the leading way by which malignancy progress in BC showing the formation of an inflammatory microenvironment that facilitates immune cell-matrix cross-talk and promotes a state of chronic inflammation. We conclude that inflammation dysregulation is an important driver of BC recurrence and progression, and that anti-inflammatory or immune checkpoint therapies should be further explored in the treatment of patients with BC.

2025-11-10 | PXD026784 | Pride

Transcriptomic Analysis Of Micropapillary High Grade T1 Urothelial Bladder Cancer

Project description:Transcriptomic Analysis Of Micropapillary High Grade T1 Urothelial Bladder Cancer

| PRJNA562495 | ENA

Transcriptomic Analysis Of Micropapillary High Grade T1 Urothelial Bladder Cancer

Project description:Management of high-grade T1 (HGT1) micropapillary bladder cancer (MPBC) is controversial. An accurate genomic characterization might help predict outcome. We analyze the transcriptomic profile of MPBC in a clinically annotated HGT1 cohort establishing correlation with clinical outcome.A retrospective analysis of prospectively clinically followed series of HGT1; 23 patients with MPBC and 64 without MPBC (reference set). We identified a set of genes differentially expressed (DE). Associations between; clinical variables and gene expression (GE) levels (Wilcoxon’s rank sum); GE and time to progression (TTP) in univariate analysis (Log rank); GE levels adjusting for clinical variables (Cox regression) were evaluated.We identified a 26-gene signature that characterized MPBC in HGT1. Several genes including CD36, FAPB3 and RAETE1 were significantly associated with TTP. High expression of FABP3 and CD36 were associated with shorter TTP (P=0.045 and P=0.08 (NS)) as was low expression of RAET1E (P=0.01). Limitations include the lack of specific quantification of the percentage of MPBC tumor >10%.

2021-01-31 | GSE136401 | GEO

Targeted sequencing of paired tumour/blood of 34 T1 stage bladder cancer patients

Project description:Stage T1 bladder cancer presents a high risk of progression and requires improved understanding. In continuation of our whole-exome sequencing study on this subtype of the disease, we carried out this targeted paired tumour/blood sequencing study including 34 T1 stage bladder cancer patients. AgilentÃ¢Â€Â™s SureDesign tool was used to design a 1.133 Mb SureSelect custom capture for all coding exons of the 140 selected candidate genes.

| EGAS00001005767 | EGA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data